<DOC>
	<DOCNO>NCT00712699</DOCNO>
	<brief_summary>This study evaluate safety effectiveness extend release mixed amphetamine salt treat preschool child attention deficit hyperactivity disorder .</brief_summary>
	<brief_title>Effectiveness Extended Release Stimulant Medication Treating Preschool Children With ADHD</brief_title>
	<detailed_description>Attention deficit hyperactivity disorder ( ADHD ) common developmental disorder affect 4 % 12 % school-aged child . Children ADHD often show symptoms hyperactivity , inattention , inability sit still , trouble listening , excessive talk , aggression . ADHD generally diagnose treated child le 6 year old symptom ADHD difficult distinguish normal behavior preschool-aged child . However , preschool child exhibit symptom indicative ADHD carefully diagnose health professional may benefit early treatment low risk functional impairment later childhood . Currently , environmental change , parent effectiveness training , behavior therapy commonly use treatment preschooler ADHD symptom , preschooler respond well behavioral intervention . These child may benefit medication treatment ; however , safety effectiveness ADHD medication treat preschool-aged child well know . Extended release mixed amphetamine salt ( XR-MAS ) , stimulant medication , commonly prescribe approved medication treat ADHD child 6 year old . Further study need determine XR-MAS affect preschool-aged child ADHD symptom . This study compare safety effectiveness XR-MAS versus placebo treat preschool child ADHD . Participation study last 6 week . All participant first undergo rigorous psychiatric assessment confirm diagnosis ADHD . Eligible participant assign randomly receive treatment either XR-MAS placebo placebo XR-MAS . Participants take assign XR-MAS placebo medication 3 week cross medication additional 3 week treatment . Rating scale score collect weekly parent teacher assess symptom response measure safety .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<criteria>Living home least 6 month parent caregiver Enrolled structured school set least 2 half day week minimum 7 peer Full Scale Intelligence Quotient ( FSIQ ) 70 great OR 72 great bilingual Best estimate diagnosis base clinical interview , Diagnostic Interview Schedule Children , Child Behavior Checklist , rating scale score Symptoms present least 9 month Meets severity criterion Clinical Global ImpressionSeverity score great equal 4 Clinical Global Assessment Scale score great equal 55 Parent/caregiver commit 6 weekly session , include initial screening exam If current psychotropic medication , undergo washout period least 3 day study entry Not currently receive psychotherapy start psychotherapy within 30 day study entry Previous nonresponse mixed amphetamine salt ( define 2 week persistent symptom spite dos great equal 15 mg per day ) Diagnosis languagebased cognitive delay 2 standard deviation sameaged peer diagnosis mental retardation Pervasive developmental disorder autism Significant developmental disorder ( e.g. , blindness , deafness , cerebral palsy , epilepsy , psychosis ) Taking another psychotropic medication discontinue Serious psychiatric disorder ( e.g. , bipolar , suicidality , tic disorder ) Actively take medication certain medical condition ( e.g. , hypertension , structural cardiac condition , glaucoma , hyperthyroidism ) Allergy mixed amphetamine salt History physical , sexual , emotional abuse clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>36 Months</minimum_age>
	<maximum_age>66 Months</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Preschool</keyword>
	<keyword>Children</keyword>
	<keyword>ADHD</keyword>
	<keyword>Medication</keyword>
	<keyword>Controlled Study</keyword>
	<keyword>Placebo</keyword>
	<keyword>Mixed Amphetamine Salts</keyword>
</DOC>